Team:USTC CHINA

From 2013.igem.org

(Difference between revisions)
 
(28 intermediate revisions not shown)
Line 8: Line 8:
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/home.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/home.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
 +
</head>
</head>
Line 69: Line 70:
       </div>
       </div>
       <div class="page-tittle" align="right">
       <div class="page-tittle" align="right">
-
         <h1>In Situ Transdermal Vaccine</h1>
+
         <h1>In Situ <span>T</span>ransdermal <span>Vaccine</span></h1>
       </div>
       </div>
       <div class="page-para" align="right">
       <div class="page-para" align="right">
-
         <p>Fresh Expression, No Purification<br />Standardization, Block-based design<br />Easy-transportation, Low Storage External Costs<br />Almost No Demand For Medical Conditions And Proferssionals<br />
+
         <p>2013, We Redefined Vaccine<br />A Revolutionary Transdermal Vaccine<br />Safe, Reliable, Needle-free and Available for Everyone<br />
         </p><p></p>
         </p><p></p>
         <p>
         <p>
Line 90: Line 91:
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <div id="abs-text">
   <div id="abs-text">
-
   We hope to provide a needle-free and non-skin-damage vaccination,
+
   We hope to develop a fresh-expression transdermal vaccination.
-
   <br />we hope everyone, even in the least developed area, could enjoy the benefit of medical progress.<br />
+
   <br />We hope everyone in this world could equally enjoy the benefit of medical progress.<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background">more about project background</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" /></div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" /></div>
Line 99: Line 100:
<div id="pro-bar">
<div id="pro-bar">
-
<h1>Design of project</h1>
+
<h1>Design of Project</h1>
   <div id="pro-text">
   <div id="pro-text">
-
   With the support of <span><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background#" target="_blank">TD-1</a></span>, a special polypeptide which can greatly facilitate macromolecule transdermal delivery through intact skin, we construct three different fuctional engineered bacillus subtilis; besides, we design a reporter system, including a kill switch, in the fouth type B.subtilis to improve usability and ensure biosafety.</div>
+
   With the support of <span><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background#" target="_blank">TD-1</a></span>, a special polypeptide which can greatly facilitate macromolecule transdermal delivery across intact skin, we constructed three different fuctional engineered <i>Bacillus subtilis</i>; besides, we designed a reporter system, including a kill switch, in the fouth type <i>B.subtilis</i> to improve usability and ensure biosafety.</div>
<div id="ls" class="pro-col">
<div id="ls" class="pro-col">
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <div id="pro-de-text">
   <div id="pro-de-text">
   <span>ANTIGEN</span><br />
   <span>ANTIGEN</span><br />
-
As the core of our in-situ system,<br /> TD1-antigen expresser is designed<br /> and will share a great percentage of<br /> the total bacteria in our "band-aid".
+
As the core of our in-situ system,<br /> TD1-antigen expresser is designed<br /> and will make up great percentage of<br />in the total bacteria in our "band-aid".
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 116: Line 117:
   <div id="pro-de-text">
   <div id="pro-de-text">
   <span>LTB</span><br />
   <span>LTB</span><br />
-
As one kind of our adjuvant expresser,<br />TD1-LTB is used to enhance the antigenicity.<br /> For LTB has so many advantages, it's a wild using adjuvant for most of exsiting injected vaccine.
+
As one kind of our adjuvant expresser,<br />TD1-LTB is used to enhance the antigenicity.<br /> For LTB has so many advantages, it's a widely used adjuvant for most of exsiting injected vaccine.
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 126: Line 127:
   <div id="pro-de-text">
   <div id="pro-de-text">
   <span>TNFα</span><br />
   <span>TNFα</span><br />
-
It's worth mentioning that to improve the effects of <br />traditional vaccine, as another kind of our TD1-adjuvant expresser, KNFα bear the weight of our hope to increase the sensitivity of our immune system.
+
TNFα is a chemotactic factor recruiting Langerhans Cells, the antigen presenting cells beneath the skin barrier. The TNFα expresser is responsible for collecting LC and triggering more intense immune responses.
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 136: Line 137:
   <div id="pro-de-text">
   <div id="pro-de-text">
   <span>REPORTER</span><br />
   <span>REPORTER</span><br />
-
Reporter, which notifies users whether the status of vaccine patch is all right and when they can stick the patches to arms .  Further more killing switch is existed in them as a biosafety guard.
+
Reporter notifies users the status of vaccine patch and when to stick.  Furthermore, it contains killing switch as a biosafety guard.
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 149: Line 150:
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <div id="exp-text">
   <div id="exp-text">
-
  <span>Molecules part</span><br />
+
  <span>Construction of Vectors</span><br />
-
We took E.coli and the PET vector as the positive control and realized our ideas in the B.subtilis expression system based on PHT43 shuttle vector.<br />
+
We took <i>E.coli</i> and the pET vector as the positive control and realized our ideas in the <div class="oblique">B.subtilis</div> expression system based on pHT43 shuttle vector.<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">more about project results</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 158: Line 159:
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <div id="exp-text">
   <div id="exp-text">
-
   <span>Protein part</span><br />
+
   <span>Tests on fusion protein</span><br />
-
   Before we achieve fresh expression, we need first use purified protein to obtain exact data to verify our assumption.<br />
+
   To achieve fresh expression ultimately, we used purified protein to obtain accurate data and verify our design.<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Results">more about project results</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 167: Line 168:
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <img class="img-left" src="https://static.igem.org/mediawiki/2013/0/02/2013ustc-china_66.png" width="16" height="14" />
   <div id="exp-text">
   <div id="exp-text">
-
   <span>Mice experiments</span><br />
+
   <span>Immunogenicity experiments</span><br />
-
   The most obvious character of our 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also tried mice experiments, which could be divided into transdermal experiments in vitro and animate mice experiments<br />
+
   The most prominent character of 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also conducted mice experiments, including in vitro transdermal experiments and mice experiments<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurthurWork">more about project results</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurthurWork">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />

Latest revision as of 03:28, 29 October 2013

USTC_China

In Situ Transdermal Vaccine

2013, We Redefined Vaccine
A Revolutionary Transdermal Vaccine
Safe, Reliable, Needle-free and Available for Everyone

Project

Motivation

We hope to develop a fresh-expression transdermal vaccination.
We hope everyone in this world could equally enjoy the benefit of medical progress.
more

Design of Project

With the support of TD-1, a special polypeptide which can greatly facilitate macromolecule transdermal delivery across intact skin, we constructed three different fuctional engineered Bacillus subtilis; besides, we designed a reporter system, including a kill switch, in the fouth type B.subtilis to improve usability and ensure biosafety.
ANTIGEN
As the core of our in-situ system,
TD1-antigen expresser is designed
and will make up great percentage of
in the total bacteria in our "band-aid".
more
LTB
As one kind of our adjuvant expresser,
TD1-LTB is used to enhance the antigenicity.
For LTB has so many advantages, it's a widely used adjuvant for most of exsiting injected vaccine.
more
TNFα
TNFα is a chemotactic factor recruiting Langerhans Cells, the antigen presenting cells beneath the skin barrier. The TNFα expresser is responsible for collecting LC and triggering more intense immune responses.
more
REPORTER
Reporter notifies users the status of vaccine patch and when to stick. Furthermore, it contains killing switch as a biosafety guard.
more

Experimental Measurement

Construction of Vectors
We took E.coli and the pET vector as the positive control and realized our ideas in the
B.subtilis
expression system based on pHT43 shuttle vector.
more
Tests on fusion protein
To achieve fresh expression ultimately, we used purified protein to obtain accurate data and verify our design.
more
Immunogenicity experiments
The most prominent character of 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also conducted mice experiments, including in vitro transdermal experiments and mice experiments
more

Retrieved from "http://2013.igem.org/Team:USTC_CHINA"